Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1985]

Treatment options for high risk relapsed/refractory multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

BCMA: A new biomarker for multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )

ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

Continuous treatment versus fixed duration therapy: Using real-world evidence...

Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin

Continuous treatment versus fixed duration therapy: Using real-world evidence to guide treatment paradigms for multiple myeloma ( Prof Evangelos Terpos, Prof Andrew Spencer and Dr Robert Rifkin )

Transitioning from bortezomib to ixazomib in patients with multiple myeloma

Dr Habte Yimer - Texas Oncology, Tyler, USA

Transitioning from bortezomib to ixazomib in patients with multiple myeloma ( Dr Habte Yimer - Texas Oncology, Tyler, USA )

Evaluating treatment options for acute myeloid leukaemia

Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA

Evaluating treatment options for acute myeloid leukaemia ( Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA )

Recent advances in smouldering and relapsed or refractory multiple myeloma

Dr Jose Sandoval - Moffitt Cancer Center, Tampa, USA

$Recent advances in smouldering and relapsed or refractory multiple myeloma ( Dr Jose Sandoval - Moffitt Cancer Center, Tampa, USA )$

Use of platform studies for the evaluation of innovative combinations in solid...

Dr Elizabeth Pease - AstraZeneca, UK

Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies ( Dr Elizabeth Pease - AstraZeneca, UK )

Implementing national cancer control plans

Dr Eduardo Cazap and Dr Lisa Stevens

Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )

Chemotherapy-free strategies in treating leukaemia

Prof Robin Foa - University of Rome, Rome, Italy

Chemotherapy-free strategies in treating leukaemia ( Prof Robin Foa - University of Rome, Rome, Italy )

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph...

Prof Robin Foa - University of Rome, Rome, Italy

Dasatinib-blinatumomab combination for the front-line treatment of adult Ph-positive ALL patients ( Prof Robin Foa - University of Rome, Rome, Italy )

More from ecancer